Management of metastatic melanoma with new immunotherapy approaches beyond PD-1/CTLA-4 inhibitors.
Curr Opin Oncol
; 34(2): 123-130, 2022 Mar 01.
Article
in En
| MEDLINE
| ID: mdl-35081051
ABSTRACT
PURPOSE OF REVIEW If we may cure metastatic melanoma patients thanks to immune checkpoint inhibitors (ICI), it is fair to say that around 2/3 of the patients present primary or secondary resistance to ICI. Therefore, progresses are needed and numerous new treatments are tested either alone or in combination with cytolytic T-lymphocyte-associated protein 4 (CTLA-4) or (PD)-1 blockade to overcome this resistance. In this review, we focused on new immunotherapeutic approaches studied in advanced melanoma previously treated by anti-PD-1 (Programmed cell Death 1 receptor) or anti-CTLA-4 antibodies. RECENT FINDINGS:
The different approaches have been classified based on 'the cancer immunity cycle'. These new strategies target either the T-cell priming and activation step, T-cell trafficking and tumor infiltration, or tumor antigen recognition by T-cell and tumor killing.SUMMARY:
Most of these novel strategies are based on mAbs targeting T-cell inhibitory or stimulatory coreceptors. The second main focus is based on modifying the tumor micro-environment. Combination strategies seem promising in few patients and suggest that a deeper understanding of the resistance in individual patients is mandatory to go further.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neoplasms, Second Primary
/
Melanoma
Limits:
Humans
Language:
En
Journal:
Curr Opin Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article
Affiliation country:
Belgium